No significant associations were seen between KRAS and GNAS mutations and the presence of adenocarcinoma in IPMN patients (OR 1.342, 95 % CI 0.878–2.050, P = 0.174, Q = 26.746, I2 = 25.222, and OR 0.548, 95 % CI 0.285–1.053, P = 0.071, Q = 10.231, I2 = 51.131, respectively). The gene discussed is KRAS; the disease is adenocarcinoma.